Suhrad G Banugaria Trusha T Patel Joanne Mackey Stuti Das Andrea Amalfitano Amy S Rosenberg Joel Charrow Y-T Chen Priya S Kishnani
10.1016/j.ymgme.2012.01.019
Mol Genet Metab
2012 Apr;105(4):677-80.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/22365055/
Antibody-Producing Cells / immunology Enzyme Replacement Therapy Glycogen Storage Disease Type II / immunology Glycogen Storage Disease Type II / therapy Immunomodulation Plasma Cells / immunology alpha-Glucosidases / immunology
Antibody-Producing Cells / immunology Enzyme Replacement Therapy Glycogen Storage Disease Type II / immunology Glycogen Storage Disease Type II / therapy Immunomodulation Plasma Cells / immunology alpha-Glucosidases / immunology Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Glycogen Storage Disease Type II / enzymology Humans Infant Male Treatment Outcome GAA protein, human alpha-Glucosidases
PMC3711263
22365055
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells
2012